SHR-1701 + bevacizumab + capecitabine + oxaliplatin

A **combination regimen** consisting of SHR-1701 (a bifunctional fusion protein targeting PD-L1 and TGF-β), **bevacizumab** (a monoclonal antibody against VEGF-A), **capecitabine** (an oral prodrug of fluorouracil), and **oxaliplatin** (a platinum-based chemotherapeutic agent) used primarily for the first-line treatment of **unresectable metastatic colorectal cancer**. SHR-1701 exerts dual antagonism—blocking PD-L1 to unleash antitumor immunity and sequestering TGF-β via the extracellular domain of TGFβ receptor II, mitigating immunosuppressive tumor microenvironment effects. Bevacizumab inhibits angiogenesis by blocking VEGF-A; capecitabine is metabolized to 5-fluorouracil, inhibiting thymidylate synthase, and oxaliplatin forms DNA crosslinks resulting in cytotoxicity. The combination demonstrates a **manageable safety profile and potent antitumor activity** with objective response rates approaching 60% in phase 2 studies for metastatic colorectal cancer[3].

Brand names

XELOX

Other names

SHR-1701 + BP102 + XELOX